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Abstract
Transforming growth factor beta 1 (TGF-h1) affects growth plate chondrocytes through Smad-mediated mechanisms and has been shown
to increase protein kinase C (PKC). This study determined if PKC mediates the physiological response of rat costochondral growth zone
(GC) chondrocytes to TGF-h1; if the physiological response occurs via type II or type III TGF-h receptors, and, if so, which receptor
mediates the increase in PKC; and the signal transduction pathways involved. Treatment of confluent GC cells with TGF-h1 stimulated
[3H]thymidine and [35S]sulfate incorporation as well as alkaline phosphatase (ALPase) and PKC specific activities. Inhibition of PKC with
chelerythrine, staurosporine, or H-7 caused a dose-dependent decrease in these parameters, indicating that PKC signaling was involved. TGF-
h1-dependent PKC and the physiological response of GC cells to TGF-h1 was reversed by anti-type II TGF-h receptor antibody and soluble
type II TGF-h receptor, showing that TGF-h1 mediates these effects through the type II receptor. The increase in [3H]thymidine
incorporation and ALPase specific activity were also regulated by protein kinase A (PKA) signaling, since the effects of TGF-h1 were
partially blocked by the PKA inhibitor H-8. The mechanism of TGF-h1 activation of PKC is through phospholipase A2 (PLA2) and not
through phospholipase C (PLC). Arachidonic acid increased PKC in control cultures and was additive with TGF-h1. Prostanoids are
required, as indomethacin blocked the effect of TGF-h1, and Cox-1, but not Cox-2, is involved. TGF-h1 stimulates prostaglandin E2 (PGE2)
production and exogenous PGE2 stimulates PKC, but not as much as TGF-h1, suggesting that PGE2 is not sufficient for all of the
prostaglandin effect. In contrast, TGF-h1 was not regulated by diacylglycerol; neither dioctanoylglycerol (DOG) nor inhibition of
diacylglycerol kinase with R59022 had an effect. G-proteins mediate TGF-h1 signaling at different levels in the cascade. TGF-h1-dependent
increases in PGE2 levels and PKC were augmented by the G protein activator GTPgS, whereas inhibition of G-protein activity via GDPhS,
pertussis toxin, or cholera toxin blocked stimulation of PKC by TGF-h1, indicating that both Gi and Gs are involved. Inhibition of PKAwith
H-8 partially blocked TGF-h1-dependent PKC, suggesting that PKA inhibition on the physiological response was via PKA regulation of
PKC signaling. This indicates that multiple interacting signaling pathways are involved: TGF-h1 stimulates PLA2 and prostaglandin release
via the action of Cox-1 on arachidonic acid. PGE2 activates the EP2 receptor, leading to G-protein-dependent activation of PKA. PKA
signaling results in increased PKC activity and PKC signaling regulates proliferation, differentiation, and matrix synthesis. D 2002 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor beta (TGF-h) is an important
regulator of chondrocyte proliferation and differentiation
that was originally purified from demineralized bone based
on its ability to stimulate the differentiation of neonatal rat
muscle cells into chondrocytes [1–3]. TGF-h also regulates
committed chondrocytes, including those in the endochon-
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dral pathway [4–6], and TGF-h1, TGF-h2, and TGF-h3 are
expressed in the resting, proliferating, and maturing zones
of the rat epiphyseal growth plate [7]. Rat costochondral
cartilage cells are particularly sensitive to TGF-h1 [6,8].
These cells respond to the growth factor in a concentration-
dependent manner. At levels as low as 0.22 ng/ml, costo-
chondral cartilage cells exhibit maximal responses with
respect to differentiation; at higher concentrations of 0.88
ng/ml, proliferation is affected. Even proliferation is regu-
lated at levels of the growth factor that are significantly
lower than are required for osteoblasts to exhibit the same
effect [9,10]. Rat articular chondrocytes also exhibit
increased proliferation in response to low concentrations
of TGF-h1 [11].
The mechanisms by which TGF-h exerts its effects on
growth plate chondrocytes are beginning to be elucidated.
The high degree of sensitivity of rat chondrocytes to TGF-
h1 and the narrow concentration ranges eliciting specific
responses in costochondral growth plate chondrocytes sug-
gest that complex signaling pathways may be involved.
There is considerable evidence that the physiological res-
ponse of cells to TGF-h1 is mediated by the type II TGF-h1
receptor [12–16] and that the biological signal of TGF-h1 is
conveyed through Smad proteins [17,18]. TGF-h receptors I
and II are expressed in resting, proliferating, and maturing
zones of the rat epiphyseal growth plate [7], suggesting that
they may also function in the costochondral cartilage as well.
Upon binding to TGF-h1, the type II receptor associates
with and activates the type I receptor; Smads 2 and 3 are
phosphorylated and translocate into the nucleus, where they
act as transcription factors [19].
It is becoming increasingly clear that Smads may not be
solely responsible for the entire effect of TGF-h1. We have
shown that TGF-h1 causes a dose-dependent increase in
protein kinase C (PKC) in costochondral chondrocytes [20]
and that PKC mediates some, but not all, of the biological
responses of costochondral cartilage resting zone chondro-
cytes to TGF-h1. Whether this is also true for cells from the
prehypertrophic and upper hypertrophic zones (growth
zone) of the growth plate is not known, nor is it known if
it is due to the action of TGF-h1 on the type II receptor.
There are a number of reasons why TGF-h1 action may
differ in resting zone and growth zone chondrocytes. TGF-
h1 causes an increase in PKCa specific activity that is
maximal at 12 h and requires gene expression and protein
synthesis in both resting zone and growth zone chondro-
cytes, but the time course of the response differs between
the two states of endochondral maturation [20]. In resting
zone cells, the increase in PKC occurs earlier and remains
elevated over a longer period of time than is seen in growth
zone cells. In both cell types, the increase in enzyme activity
is due to new cytosolic PKC and only minimally to the
translocation of existing PKC to the plasma membrane.
There are some differences in the mechanisms involved in
TGF-h1-dependent PKC activation in resting zone and
growth zone cells, however. Inhibition of phosphatidylino-
sitol-specific phospholipase C (PI-PLC) caused a small, but
significant, dose-dependent increase in PKC in growth zone
cells, and inhibition of tyrosine kinase caused a similar
increase in PKC in resting zone cells [20].
Other signaling pathways may also be involved as well.
Whereas the effect of TGF-h1 on proteoglycan production
in resting zone chondrocytes is PKC-dependent, inhibition
of PKC does not affect the TGF-h1-stimulated increase in
proliferation or alkaline phosphatase (ALPase) activity. One
possibility is that protein kinase A (PKA) mediates at least
part of the response to TGF-h1. Studies examining the
physiological effects of TGF-h1 in rat articular chondro-
cytes support this hypothesis [11]. TGF-h1 causes a rapid
increase in c-fos expression in these cells that is followed by
an increase in [3H]thymidine incorporation. The PKC inhib-
itor H7 blocks the effect, implicating PKC in the mecha-
nism. However, these investigators used concentrations of
H-7 that also block PKA [21], so it is not clear whether PKC
or PKA was involved in the rapid response to the growth
factor. Specific inhibition of PKA also inhibits the stimula-
tory effect of TGF-h1 on proliferation and ALPase in
costochondral cartilage resting zone cells [22].
Both PKC and PKA signaling can lead to activation of
MAP kinase [23,24]. TGF-h1 has been shown to activate
the Ras-Raf-MEK-ERK MAP kinase pathway [25–27], and
activation of MAP kinase is via PKC [28]. These observa-
tions suggest that receptor binding may regulate the phys-
iology of growth plate chondrocytes through PKC and
PKA, in addition to using Smad proteins. It is not known
which receptor is responsible for the TGF-h1 effect on PKC
or on PKC-dependent physiological responses.
Phospholipase A2 (PLA2), arachidonic acid, and prosta-
glandin E2 (PGE2) may also play a role in the mechanism by
which TGF-h1 regulates PKC in growth zone chondrocytes.
We recently showed that TGF-h1 causes an increase in
PGE2 production in resting zone cells, and this is further
increased by PKC inhibition [29]. The increase in PGE2 was
due to an increase in PLA2 activity rather than an increase in
arachidonic acid metabolism. In addition, exogenous arach-
idonic acid inhibited TGF-h1-dependent stimulation of
PKC. Whether this is also true for growth zone chondro-
cytes is not known, but there are a number of reasons to
expect it not to be. Arachidonic acid decreases PKC in
resting zone cells, but increases enzyme activity in growth
zone cells [30]. PGE2 signals through its EP1 receptor to
decrease PKC in resting zone cells [31], whereas in growth
zone cells, PGE2 stimulates PKC [30]. Moreover, many of
the physiological responses of resting zone cells and growth
zone cells to TGF-h1 differ [8,32], supporting the hypoth-
esis that different receptor-mediated pathways are involved.
This study tested the hypothesis that TGF-h1 acts on
costochondral growth zone (GC) chondrocytes via the TGF-
h1 type II receptor. The physiological responses of the cells
are mediated by PKC and PKA in a mechanism that
involves PLA2 through the release of arachidonic acid and
prostaglandin production. Moreover, regulation of PKC by
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TGF-h1 and the signaling pathways responsible depend on
the maturation state of the responding chondrocyte.
2. Materials and methods
2.1. Reagents
The following chemicals were purchased from Sigma
Chemical (St. Louis, MO): PGE2, indomethacin (a general
cyclooxygenase inhibitor), and reagents for the ALPase
assay. The following chemicals were purchased from Cal-
biochem (San Diego, CA): 1,2-dioctanoyl-sn-glycerol
(DOG), R59022 (diacylglycerol kinase inhibitor), cheler-
ythrine, staurosporine, and H-7 (PKC inhibitors), H-8 (PKA
inhibitor), arachidonic acid, pertussis toxin (Gi inhibitor),
choleratoxin (Gs inhibitor), GDPhS (general G-protein
inhibitor), GTPgS (G-protein activator), resveratrol (Cox-1
inhibitor), and NS-398 (Cox-2 inhibitor). PKC assay
reagents and Dulbecco’s modified Eagle medium (DMEM)
were obtained from GIBCO-BRL (Gaithersburg, MD). The
protein content of each sample was determined using the
bicinchoninic acid (BCA) protein assay reagent [33]
obtained from Pierce Chemical (Rockford, IL). Recombi-
nant human TGF-h1, anti-TGF-h1 receptor II and receptor
III antibodies, and soluble TGF-h1 receptor II and receptor
III were obtained from R&D Systems (Minneapolis, MN).
Fetal bovine serum (FBS) was purchased from Atlanta
Biologicals (Norcross, GA). The PGE2 radioimmunoassay
kit, [3H]thymidine, [35S]sulfate, and [32P]ATP were
obtained from NEN-DuPont (Boston, MA).
2.2. Chondrocyte cultures
The rat costochondral chondrocyte culture system used in
this study has been described in detail previously [34]. Cells
were derived from the growth zone (prehypertrophic and
upper hypertrophic cell zones) of costochondral cartilage
from 125-g male Sprague-Dawley rats (Harlan, Indianapolis,
IN) and cultured in DMEM containing 10% FBS, 50 Ag/ml
vitamin C, and antibiotics. Confluent, fourth passage cells
were used for all experiments. The characteristics of these
cells have been well described [35,36]. Although they
express mRNA for type X collagen based on RT-PCR
(unpublished data), they do not produce type X collagen
based on SDS-PAGE [37]. The cells produce type II collagen,
synthesize sulfated glycosaminoglycans, and form cartilage
nodules when implanted in nude mouse thigh muscle.
2.3. Role of TGF-b1 receptors in physiologic response of
growth zone cells to TGF-b1
To determine whether the response of growth zone cells
to TGF-h1 involves the type II or type III TGF-h1 receptor,
cultures were incubated with 0.11, 0.22, or 0.88 ng/ml TGF-
h1F0.5, 1 or 2 Ag/ml anti-type II receptor or anti-type III
receptor antibodies, or with 25, 50 or 100 Ag/ml soluble type
II or III receptors for 24 h. Changes in [3H]thymidine
incorporation, proteoglycan sulfation, and ALPase specific
activity were assessed. We did not specifically examine the
role of the type I receptor since antibodies to this receptor
were not available. We did not include cultures treated with
nonspecific IgG1 because previous studies failed to show an
effect on any of the parameters we examined [38].
2.3.1. [3H]thymidine incorporation
DNA synthesis was assessed by measuring [3H]thymi-
dine incorporation into trichloroacetic acid (TCA) insoluble
cell precipitates as described previously [39]. Quiescence
was induced by incubating cultures for 48 h in DMEM
containing 1% FBS. The medium was then replaced for 24 h
with DMEM containing 1% FBS, vehicleFTGF-h1, and
the appropriate concentration of soluble receptor or anti-
receptor antibody. Two hours prior to harvest, [3H]thymi-
dine was added. Radioactivity in TCA-precipitable material
was measured by liquid scintillation spectroscopy.
2.3.2. [35S]sulfate incorporation
Proteoglycan synthesis was assessed by measuring
[35S]sulfate incorporation using a modification of the
method of O’Keefe et al. [40] as described previously
[41,42]. At confluence, fresh medium containing vehi-
cleFTGF-h1Fsoluble receptors or anti-receptor antibodies
was added to the cells and the incubation continued for an
additional 24 h. Four hours prior to harvest, 50 Al DMEM
containing 18 ACi/ml [35S]sulfate and 0.814 mM carrier
sulfate were added to each culture. At harvest, the condi-
tioned media were removed, the cell layers (cells and
matrix) collected, and the amount of [35S]sulfate incorpo-
rated determined by liquid scintillation spectrometry. The
protein content was determined using the BCA protein assay
and the data expressed as disintegrations per minute per
milligram protein in the cell layer.
2.3.3. ALPase activity
ALPase [orthophosphoric monoester phosphohydrolase,
alkaline (EC 3.1.3.1)] was measured as a function of release
of para-nitrophenol from para-nitrophenylphosphate at pH
10.2 [43]. Enzyme activity was assayed in lysates of the cell
layer, as well as in isolated matrix vesicle and plasma
membranes as previously described [44]. Cultures were
treated with 0.11, 0.22, or 0.88 ng/ml TGF-h1Fsoluble
receptors or anti-receptor antibodies.
2.4. Role of PKC in physiologic response of growth zone
cells to TGF-b1
To determine whether the response of growth zone cells
to TGF-h1 involves PKC, cultures were incubated with
0.11, 0.22, or 0.88 ng/ml TGF-h1FPKC inhibitors. We used
1 and 10 AM chelerythrine as an inhibitor of PKC because
of its relative specificity for the enzyme [45]. In some
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experiments, cells were cultured with 0.01 or 0.1 AM
staurosporine [46] or 1, 5, or 10 AM H-7 [21] to inhibit
PKC. All three inhibitors have been shown to cause dose-
dependent decreases in PKC activity of growth zone cell
cultures [47]. [3H]thymidine incorporation, [35S]sulfate
incorporation, and ALPase were measured as described
above.
2.5. PGE2 production
Because PGE2 is a regulator of growth zone chondro-
cytes [48] and is involved in the rapid activation of PKC in
these cells in response to other mediators [49], we examined
whether TGF-h1 increases PGE2 production as well. PGE2
production by growth zone chondrocyte cultures treated
with TGF-h1 was assessed by using a radioimmunoassay
kit (NEN DuPont) as described previously [50]. PGE2 has
been shown to regulate physiologic responses of growth
zone chondrocytes by signaling through the EP1 receptor
[51], which signals through the Gq/PLC pathway to activate
PKC [52]. To clarify whether the effect of TGF-h1 on PGE2
production was before or after G-protein activation or PKC
activation, confluent cultures were treated for 24 h with 0.22
ng/ml TGF-h1 in the presence or absence of 1, 10 or 100
AM GTPgS (general G-protein activator) or chelerythrine
(PKC inhibitor).
2.6. Role of PKA
PGE2 exerts its effects on growth zone cells via the EP1
receptor through both PKC- and PKA-dependent mecha-
nisms [51]. To assess the role of PKA in cell response to
TGF-h1, growth zone chondrocytes were incubated with
TGF-h1F1, 5, or 10 AMH-8 [21]. H-8 inhibits PKAwith an
IC50 of 1.2 AM. In contrast, the IC50 for PKC is 15 AM, and
the IC50 for MLCK is 68 AM [53], well above the concen-
trations used in this study. [3H]thymidine incorporation was
examined in cultures treated with 0.88 ng/ml TGF-h1, and
ALPase specific activity was measured in cultures treated
with 0.22 ng/ml TGF-h1 based on prior studies, indicating
that maximal effects of TGF-h1 on these parameters occur
at these concentrations [6,54]. Assays were performed as
described above.
2.7. TGF-b1-dependent regulation of PKC
2.7.1. PKC specific activity
PKC specific activity was assayed as described previ-
ously [20]. Cell layer lysates containing equivalent amounts
of protein were mixed for 20 min with a lipid preparation
containing phorbol-12-myristate-13-acetate, phosphatidyl-
serine, and Triton X-100 mixed micelles to provide the
necessary cofactors and conditions for optimal enzyme
activity [55]. To this mixture, a high-affinity myelin basic
protein peptide and [32P]ATP (25 ACi/ml) were added to a
final assay volume of 50 Al. Following a 10-min incubation
at 30 jC, samples were spotted onto phosphocellulose discs,
which were then washed twice with 1% phosphoric acid and
once with distilled water to remove unincorporated label
prior to placement in a scintillation counter.
2.7.2. Effect of arachidonic acid, prostaglandins, and PGE2
To assess the role of arachidonic acid in TGF-h1-depend-
ent PKC stimulation, confluent cultures were treated for 12
h with vehicle alone or with 0.22 ng/ml TGF-h1 in the
presence or absence of 1, 10 or 100 AM arachidonic acid.
Control cultures were treated with TGF-h1+the arachidonic
acid vehicle (0.02% ethanol in DMEM). To determine if
prostaglandin mediates the effects of TGF-h1 on PKC,
growth zone chondrocytes were incubated in the presence
or absence of 0.1, 1, or 10 AM indomethacinF0.22 ng/ml
TGF-h1 for 12 h. Indomethacin blocks both Cox-1 and
Cox-2 [56]. The relative contributions of Cox-1 and Cox-2
were determined using resveratrol (0.1, 1, and 10 AM) and
NS-398 (0.1, 1, and 10 AM) to inhibit the constitutive and
inducible forms of the enzyme, respectively. The specific
role of PGE2 was determined by treating the cultures with
vehicleF0.22 ng/ml TGF-h1F15, 60, or 240 pg/ml PGE2.
2.7.3. Effect of diacylglycerol
Diacylglycerol activates PKC in a number of cells,
including growth zone chondrocytes [47]. This is generally
a rapid effect due to rapid Gq-dependent activation of PLC
[47]. DAG then binds to PKC, activating translocation of
PKC to the plasma membrane [57]. Our previous studies
showed that PLC was not involved in the mechanism of
TGF-h1-dependent PKC activation [20]. Thus, if diacylgly-
cerol was involved, it must be generated through another
pathway. Diacylglycerol can also be produced through
phospholipase D (PLD) via a mechanism involving PLD2
[58], but this pathway may not occur with the same rapidity
as via PLC. To determine if diacylglycerol is involved in
TGF-h1 action, we examined the effects of DOG, a cell-
permeable form of the PKC activator [57], and the diacyl-
glycerol kinase inhibitor R59022, which maintains elevated
diacylglycerol levels [59]. R59022 blocks the conversion of
diacylglycerol species to phosphatidic acid and is relatively
promiscuous about the source of the diacylglycerol [59–61].
We did not use butan-1-ol to block PLD [62] because
butanol is toxic to the cells. Cultures were treated with
vehicleF0.11 or 0.22 ng/ml TGF-h1 in the presence or
absence of 1, 10, or 100 AM DOG or 5, 10, or 50 AM
R59022. Control cultures were treated with TGF-
h1Fvehicle (0.02% ethanol in DMEM). PKC activity was
measured at 12 h.
2.7.4. Direct effect of TGF-b1 on membrane-associated
PKC
PKC activity of membranes increases in response to a
stimulus due to translocation of the activated cytosolic
enzyme to the membrane [63]. However, previous studies
in our laboratory showed that TGF-h1-dependent increases
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in PKC are not due to translocation [20]. To determine
whether TGF-h1 regulates PKC activity by direct action on
membrane-associated enzyme, isolated plasma membranes
and matrix vesicles were incubated directly with TGF-h1.
Both membrane fractions have been shown previously to
contain PKCa and PKC~ [64]; PKCa predominates in
plasma membranes, whereas PKC~ predominates in matrix
vesicles. Because matrix vesicles are extracellular, they are
right side out when they are isolated. They do not contain
RNA or DNA, so new gene expression or protein synthesis
cannot occur. Therefore, any effect of TGF-h1 on PKC is by
direct action on the membrane.
For these experiments, confluent, fourth passage growth
zone cells were released from their matrix by trypsin
digestion and collected by centrifugation. Plasma mem-
branes were isolated by differential and sucrose density
gradient centrifugation of homogenized cells [44,65].
Matrix vesicles were isolated by differential centrifugation
of the trypsin-digested matrix [66]. Following assay for
protein content [33], plasma membranes or matrix vesicles
were suspended in 0.9% NaCl and frozen at 70 jC. Matrix
vesicles isolated in this manner typically exhibit greater than
two-fold enrichment of ALPase specific activity when
compared with the plasma membranes and have a trans-
mission electron microscopic appearance consistent with
matrix vesicles in vivo [66]. Matrix vesicles or plasma
membranes (10 Ag protein in 0.9% NaCl containing 10%
FBS) were incubated in the absence (vehicle only) or
presence of a final concentration of 0.11, 0.22, or 0.88 ng/
ml TGF-h1 for either 9, 90, or 270 min at 37 jC as
described previously [64]. Following incubation, samples
were assayed for PKC activity.
2.8. Statistical analysis
Unless otherwise noted, the data presented below are
from one of three or more independent experiments, all
showing comparable results. Each data point represents the
Fig. 1. Effect of TGF-h1 receptor II antibody on TGF-h1-induced [3H]thymidine incorporation (A); [35S]sulfate incorporation (B); alkaline phosphatase
activity (C); and PKC activity (D). Confluent growth zone cells were treated with control media or TGF-h1 in the absence and presence of TGF-h1 receptor II
antibody as described in Materials and methods. Values are the meanFS.E. of six independent cultures. Data are from one of two separate experiments, both
with comparable results. *P<0.05, vs. no treatment with antibody; #P<0.05, vs. no treatment with TGF-h1.
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meanFS.E. for six cultures (N=6). For membrane PKC
assays, each data point is the meanFS.E. for six membrane
preparations, where each preparation was derived from one
T-150 flask of cells. Data were analyzed by ANOVA.
Statistical significance was determined using Bonferroni’s
modification of Student’s t-test, with P<0.05 being consid-
ered significant.
3. Results
3.1. Role of TGF-b1 receptors in physiologic response of
growth zone cells to TGF-b1
TGF-h1 mediates its effects on growth zone chondrocytes
via its type II receptor. Antibodies to the TGF-h1 type II
receptor (Fig. 1), as well as soluble type II receptor (Fig. 2),
caused a dose-dependent decrease in TGF-h1-stimulated
[3H]thymidine incorporation (Figs. 1A and 2A), proteogly-
can sulfation (Figs. 1B and 2B), ALPase specific activity
(Figs. 1C and 2C), and PKC specific activity (Figs. 1D and
2D). The inhibitory effect of the soluble receptor on the
response of growth zone cells to TGF-h1 was only partial
with respect to [35S]sulfate incorporation and PKC activity
(Fig. 2B,D). Similarly, TGF-h1-dependent increases in PKC
were elevated over control levels, even at the highest con-
centration of antibody used (Fig. 1D). Neither the antibody
nor the soluble receptor affected these parameters in control
cultures. In contrast to TGF-h receptor II antibody, TGF-h
receptor III antibody had no significant effect on PKC
specific activity in either control cultures or cultures treated
with 0.22 ng/ml TGF-h1 (data not shown).
3.2. Role of PKC in cell response to TGF-b1
The physiological response to TGF-h1 was PKC-
dependent (Fig. 3). Chelerythrine reduced the TGF-h1-
dependent increase on [3H]thymidine incorporation (Fig.
3A), [35S]sulfate incorporation (Fig. 3B), and ALPase
specific activity (Fig. 3C). The PKC-dependent effects of
TGF-h1 on [3H]thymidine incorporation were confirmed
using the PKC inhibitors staurosporine (data not shown) and
Fig. 2. Effect of TGF-h1 soluble type II receptor on TGF-h1-induced [3H]thymidine incorporation (A); [35S]sulfate incorporation; (B); alkaline phosphatase
activity (C); and PKC activity (D). Confluent growth zone cells were treated with control media or TGF-h1 in the absence and presence of 25, 50 or 100 Ag/ml
soluble type II receptor as described in Materials and methods. Each data point is the meanFS.E. of six independent cultures. Data are from one of two
separate experiments, both with comparable results. *P<0.05, vs. no treatment with soluble receptor; #P<0.05, vs. no treatment with TGF-h1.
E. Rosado et al. / Biochimica et Biophysica Acta 1590 (2002) 1–156
H-7 (Table 1). Similarly, H-7 blocked the effects of TGF-h1
on ALPase (Table 2).
Part of the physiological response to TGF-h1 was also
mediated via a PKA-dependent mechanism. H-8, a specific
Fig. 3. Effect of PKC inhibitor chelerythrine on TGF-h1-induced [3H]thy-
midine incorporation (A); [35S]sulfate incorporation (B); and alkaline
phosphatase specific activity (C). Confluent growth zone cells were treated
for 24 h with control media or 0.11, 0.22, or 0.88 ng/ml TGF-h1 in the
presence and absence of 1 or 10 AM chelerythrine (CE). Values are the
meanFS.E. of six independent cultures. Data are from one of two separate
experiments, both with comparable results. *P<0.05, vs. no treatment
with TGF-h1; #P<0.05, vs. no treatment with PKC inhibitor.
Table 1
Effect of protein kinase inhibitors on TGF-h1-induced [3H]thymidine
incorporation
Effector [3H]thymidine incorporation,
DPM/well (104)
Control 1.34F0.03
PKC inhibitor (H-7)
1 AM 1.36F0.02
5 AM 1.38F0.03
10 AM 1.40F0.04
PKA inhibitor (H-8)
1 AM 1.35F0.06
5 AM 1.50F0.04
10 AM 1.37F0.02
TGF-h1 (0.88 ng/ml) 4.24F0.20*
TGF-h1+1 AM H-7 2.85F0.46*,#
TGF-h1+5 AM H-7 2.20F0.71*,#
TGF-h1+10 AM H-7 1.40F0.37*,#
TGF-h1+1 AM H-8 3.82F0.36*
TGF-h1+5 AM H-8 3.38F0.36*,#
TGF-h1+10 AM H-8 3.02F0.29*,#
Confluent growth zone cells were treated for 24 h with control media or
0.88 ng/ml TGF-h1 in the absence and presence of 1, 5, and 10 AM H-7, a
PKC inhibitor, or H-8, a PKA inhibitor. At harvest, [3H]thymidine
incorporation in the cell layer was measured. Each value is the meanFS.E.
of six independent cultures. Data are from one of two separate experiments,
both with comparable results.
* P<0.05, treatment vs. control.
# P<0.05, TGF-h1+inhibitor vs. TGF-h1 alone.
Table 2
Effect of protein kinase inhibitors on TGF-h1-induced alkaline phosphatase
specific activity
Effector Alkaline phosphatase specific
activity (Amol Pi/mg protein/min)
Control 6.92F0.43
PKC inhibitor (H-7)
1 AM 7.37F0.30
5 AM 6.78F0.29
10 AM 5.56F0.67*
PKA inhibitor (H-8)
1 AM 7.07F0.62
5 AM 6.91F0.71
10 AM 5.81F0.53*
TGF-h1 (0.22 ng/ml) 11.79F0.60*
TGF-h1+1 AM H-7 8.67F0.50*,#
TGF-h1+5 AM H-7 7.94F0.80#
TGF-h1+10 AM H-7 7.31F0.55#
TGF-h1+1 AM H-8 9.45F0.22*,#
TGF-h1+5 AM H-8 8.64F0.19*,#
TGF-h1+10 AM H-8 8.16F0.72*,#
Confluent growth zone cells were treated for 24 h with control media or
0.22 ng/ml TGF-h1 in the absence and presence of 1, 5, and 10 AM H-7, a
PKC inhibitor, or H-8, a PKA inhibitor. At harvest, alkaline phosphatase
specific activity in the cell layer was measured. Each value is the
meanFS.E. of six independent cultures.
* P<0.05, treatment vs. control.
# P<0.05, TGF-h1+inhibitor vs. TGF-h1 alone.
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inhibitor of PKA reduced TGF-h1-stimulated [3H]thymi-
dine incorporation by approximately 30% (Table 1). H-8
also partially blocked the TGF-h1-stimulated increase in
ALPase specific activity (Table 2).
The production of PGE2 by growth zone chondrocyte
cultures was increased by TGF-h1 in a biphasic manner
(Fig. 4A). Significant increases in PGE2 production were
observed for cultures treated with 0.12, 0.22, and 0.5 ng/ml
TGF-h1. PGE2 production varied with time of treatment
(Fig. 4B). In control cultures, PGE2 levels were increased by
12 h and remained elevated at 24 h. Treatment with TGF-h1
(0.22 ng/ml) caused a robust increase in PGE2 production at
all times examined. At 3 h, there was a 400% increase; at 6
h, there was a 300% increase; at 12 h, the increase was more
than 100%; and at 24 h, the increase was slightly more than
50% over control cultures.
The effect of TGF-h1 on PGE2 production was G-protein-
dependent (Fig. 4C). The G-protein activator GTPgS had no
effect on basal PGE2 production, but increased TGF-h1-
induced PGE2 production in a dose-dependent manner.
Maximal increases were observed in cultures treated with
10 AM GTPgS. In contrast, PGE2 production in response to
TGF-h1 was not mediated by PKC. Inhibition of PKC with 1
AM chelerythrine had no effect on PGE2 production in either
control cultures or cultures treated with TGF-h1 (data not
shown). Interestingly, there was a slight, but statistically
significant, decrease in PGE2 in control cultures at 10 and
100 AM chelerythrine.
3.3. Mechanism of action of TGF-b1 on PKC activity
TGF-h1 regulates PKC activity through a PLA2-depend-
ent signaling pathway. Arachidonic acid, the product of
PLA2 action, increased PKC activity in growth zone chon-
drocytes, and at the highest concentration examined, the
stimulatory effect of the fatty acid was additive with that of
TGF-h1 (Table 3). Part of the effect of arachidonic acid may
be due to its metabolism by cyclooxygenase and production
of prostaglandin. Inhibition of cyclooxygenase with indo-
methacin, which inhibits both Cox-1 and Cox-2, reduced
TGF-h1-induced PKC activity in a dose-dependent manner
(Fig. 5A). PKC activity in control cultures was reduced by
34% at the highest concentration used, and TGF-h1-induced
activity was reduced by 61%. The cyclooxygenase respon-
sible was Cox-1, since the Cox-1 inhibitor, resveratrol,
significantly reduced basal PKC activity at 10 AM by
30%, and reduced TGF-h1-induced activity at 1 and 10
AM by up to 60% (Fig. 5B). The Cox-2 inhibitor NS-398
had no effect on PKC activity in either control or TGF-h1-
treated cultures (Fig. 5C).
Some of the prostaglandin-mediated effect may be due to
PGE2. PGE2 dose-dependently increased PKC activity in
control cultures (Table 3). Further, the effect due to PGE2
was less than half as robust as the effect due to TGF-h1.
Moreover, PGE2 had no effect on the increase in activity
elicited by TGF-h1.
Fig. 4. Effect of TGF-h1 on PGE2 production. Confluent growth zone cells
were treated for 12 h with control media or media containing 0.03–4 ng/ml
TGF-h1 (Panel A). Alternatively, cells were treated with control media or
media containing 0.22 ng/ml TGF-h1 for 3, 6, 12, or 24 h (Panel B). The
role of G-protein activation was examined using the G-protein activator
GTPgS. Confluent growth zone cells were treated for 12 h with control
media or 0.22 ng/ml TGF-h1 in the presence and absence of 1, 10, or 100
AM GTPgS (Panel C). At harvest, cultures were assayed for PGE2 release
into the media. Values are the meanFS.E. of six independent cultures. Data
are from one of two separate experiments, both with comparable results.
*P<0.05, vs. control (Panel A); 3 h (Panel B); or no activator (Panel C).
#P<0.05, vs. not treated with TGF-h1.
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The effect of TGF-h1 on PKC does not involve diac-
ylglycerol, indicating that the PLC and PLD signaling
pathways do not play a role. DOG caused a dose-dependent
increase in PKC activity at 90 min, as did treatment of the
cells with the diacylglycerol kinase inhibitor R59022, but
TGF-h1 had no effect at that time (data not shown). In
cultures treated with TGF-h1+DOG or R59022, only the
effect of diacylglycerol was evident. In contrast, at 12 h,
neither DOG nor R59022 affected PKC, and neither agent
altered the stimulatory effect of TGF-h1 (data not shown).
G-proteins are involved in the action of TGF-h1 on PKC
activity in growth zone chondrocytes. Pertussis toxin (Fig.
6A), which targets Gi-proteins, and cholera toxin (Fig. 6B),
which targets Gs-proteins, both increased PKC activity
slightly in control cultures, but reduced TGF-h1-induced
PKC activity in a dose-dependent manner. At the highest
concentrations examined, both inhibitors completely
blocked the stimulatory effect of TGF-h1 on PKC. These
observations were confirmed using the general G-protein
inhibitor GDPhS (Fig. 6C). Whereas GDPhS had no effect
on PKC in control cultures, it caused a dose-dependent
decrease in TGF-h1-stimulated PKC. At the highest con-
centration used, the effect of TGF-h1 was completely
blocked. In contrast, the G-protein activator GTPgS caused
a dose-dependent increase in TGF-h1-stimulated PKC
activity (Fig. 6D).
PKA is involved in TGF-h1 regulation of PKC activity
in growth zone cells. The PKA inhibitor H-8 caused a small,
Table 3
Effect of arachidonic acid and PGE2 on TGF-h1-induced PKC specific
activity
Effector Protein kinase C specific activity
(pmol PO4/Ag protein/min), 12 h
Control 0.48F0.04
Arachidonic acid (AA)
1 AM 0.49F0.03
10 AM 0.63F0.04*
100 AM 0.86F0.06*,+
PGE2
0.015 ng/ml 0.61F0.02*
0.06 ng/ml 0.69F0.06*,^
0.24 ng/ml 0.74F0.06*,^
TGF-h1 (0.22 ng/ml) 1.61F0.30*
TGF-h1+1 AM AA 1.77F0.36*
TGF-h1+10 AM AA 1.84F0.09*
TGF-h1+100 AM AA 2.49F0.39*,#
TGF-h1+0.015 ng/ml PGE2 1.59F0.11*
TGF-h1+0.06 ng/ml PGE2 1.50F0.14*
TGF-h1+0.24 ng/ml PGE2 1.60F0.20*
Confluent growth zone cells were treated for 12 h with control media or
0.22 ng/ml TGF-h1 in the absence and presence of 1, 10, or 100 AM
arachidonic acid or 0.015, 0.06, or 0.24 ng/ml PGE2. At harvest, PKC-
specific activity in the cell layer was determined. Each value is the
meanFS.E. of six independent cultures. Data are from one of two separate
experiments, both with comparable results.
* P<0.05, vs. control.
+ P<0.05, vs. 1 AM AA.
^ P<0.05, vs. 0.015 ng/ml PGE2.
# P<0.05, vs. TGF-h1 alone.
Fig. 5. Effect of cyclooxygenase inhibitors on TGF-h1-induced PKC
activity. Confluent growth zone cells were treated for 12 h with control
media or 0.22 ng/ml TGF-h1 in the presence and absence of 0.1, 1.0, or 10
AM indomethacin (Panel A), resveratrol (Panel B), or NS-398 (Panel C). At
harvest, PKC activity in the cell layer was determined. Values are the
meanFS.E. of six independent cultures. Data are from one of two separate
experiments, both with comparable results. *P<0.05, vs. no inhibitor;
#P<0.05, vs. not treated with TGF-h1.
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but significant, dose-dependent decrease in PKC in control
cultures and reduced TGF-h1-induced PKC activity by
more than 60% (data not shown).
3.4. Direct effect of TGF-b1 on membrane PKC
The effects of TGF-h1 on PKC are not mediated by a
direct effect on preexisting membrane-associated PKC. There
was no change in PKC specific activity of isolated matrix
vesicles or plasma membranes that were incubated directly
with TGF-h1 (data not shown). In addition, TGF-h1 did not
elicit a series of membrane-mediated events leading to an
increase in preexisting membrane-associated PKC, since
specific activity did not change as a function of time (data
not shown).
4. Discussion
This study demonstrates that TGF-h1 mediates its effects
on proliferation, proteoglycan production, and ALPase activ-
ity of GC chondrocytes by a mechanism involving TGF-h
receptor II, as has been noted previously by others [12–16].
Blockade of TGF-h1 type II receptor activation with anti-
bodies to the receptor or with soluble receptor blocked the
effects of the growth factor on proliferation and ALPase.
However, the stimulatory effect of TGF-h1 on [35S]sulfate
incorporation was only partially reduced. One possibility is
that expression and synthesis of aggrecan, the cartilage
proteoglycan core protein, is regulated via the type II receptor
[12], whereas glycosaminoglycan synthesis and/or sulfation
is only partially regulated in this manner. It is more likely that
this parameter is less sensitive to the concentration range
used. The type III receptor does not appear to be involved
since antibodies to this receptor had no effect.
Although Smad signaling is clearly important in cell
response to TGF-h1 [19,67], the results of the present study
show that other signaling pathways are involved. The effects
of TGF-h1 on the parameters examined here are mediated by
PKC-dependent signal transduction. Binding of TGF-h1 to
the type II receptor is required for activation of PKC, and
inhibition of PKC blocks the stimulatory effects of TGF-h1
on proliferation, proteoglycan sulfation, and ALPase activity.
Not all of the physiological responses of growth zone
cells to TGF-h1 are mediated by PKC, however. TGF-h1
caused an increase in PGE2 production that was independent
Fig. 6. Role of G-proteins in TGF-h1-induced PKC activity. Confluent growth zone cells were treated for 12 h with control media or 0.22 ng/ml TGF-h1 in the
presence and absence of 1, 10, or 100 ng/ml pertussis toxin to inhibit Gi (Panel A) or cholera toxin to inhibit Gs (Panel B). In addition, the general G-protein
inhibitor GDPhS (Panel C) or the G-protein activator GTPgS (Panel D) was tested at 1, 10, or 100 AM. At harvest, PKC activity in the cell layer was
determined. Values are the meanFS.E. of six cultures. Data are from one of two separate experiments, both with comparable results. *P<0.05, vs. no
inhibitor or activator; #P<0.05, vs. not treated with TGF-h1.
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of PKC, but depended instead on G-proteins. PKA also
plays a role since inhibition of this signaling pathway
caused a partial reduction in the stimulatory effect of
TGF-h1 on proliferation and ALPase activity. PKA may
mediate the response of growth zone cells to TGF-h1
directly or indirectly through modulation of PKC, based
on the decrease in TGF-h1-stimulated PKC activity in
cultures treated with the PKA inhibitor H-7.
Our study relies on the use of selective inhibitors to
resolve the contributions of PKC and PKA signaling to the
physiological responses of growth zone cells to TGF-h1.
Studies of this kind are complicated by the overlapping
sensitivities of these enzymes to the inhibitors used. To
overcome this concern, we used concentrations that were
optimized for the specific signaling pathway being exam-
ined. For example, chelerythrine has an IC50 of 0.7 AM for
PKC, whereas its IC50 for PKA is 170 AM [45]; the highest
concentration of chelerythrine used here was 1 AM. More-
over, we verified the contribution of the PKC signaling
pathway to the physiological response using alternate inhib-
itors, again taking care to use doses optimized for PKC. H-7
has been used effectively in other systems to block PKC
activity in the same dose range as used in our study [68–
70]. H-7 also inhibits other kinases, however, including
PKA, PKB, and myosin light chain kinase (MLCK) [69],
but the concentrations of H-7 required to do so are consid-
erably greater than the highest dose used in the present
study. Similarly, staurosporine can inhibit other serine/
threonine kinases as well as some tyrosine kinases. The
doses used in our study are appropriate for PKC, however,
since staurosporine inhibits PKC with an IC50 of 0.7 nM and
inhibits PKG with an IC50 of 85 nM [71,72]. Inhibition of
tyrosine kinases requires 25–50 AM. Finally, we used H-8
to specifically inhibit PKA. Although this approach is
cumbersome, it strengthens the interpretation of the result.
The involvement of both signaling pathways is supported
by the observations of Osaki et al. [11] using rat articular
chondrocytes. These investigators showed that 1 ng/ml
TGF-h1 caused a rapid increase in c-fos expression, and
at 18–24 h, [3H]thymidine incorporation was increased.
When the articular chondrocytes were treated with 50 AM
H-7, the stimulatory effect of TGF-h1 on DNA synthesis
was blocked. The levels of H-7 used exceeded the IC50 for
PKA (6.0 AM) as well as the IC50 for PKC (3.0 AM),
thereby implicating both kinases in the mechanism.
These observations also support the hypothesis that differ-
ent signaling pathways mediate the effects of TGF-h1 in
resting zone and growth zone chondrocytes. In the less
mature resting zone cells, neither TGF-h1-dependent prolif-
eration nor ALPase requires PKC [29], whereas both param-
eters are mediated by PKC in growth zone cells. Moreover,
part of the effect of TGF-h1 on proliferation and ALPase
activity in growth zone cells is mediated by PKA.
The mechanism of PKC activation by TGF-h1 in growth
zone cells differs from the classical pathway of PKC
activation, in which PLC or PLD act on membrane phos-
pholipids to generate the second messenger, diacylglycerol,
which then binds and activates PKC [73]. In the present
study, we show that diacylglycerol is not involved in the
TGF-h1-dependent activation of PKC since exogenous
diacylglycerol had no effect on TGF-h1-stimulated PKC.
Moreover, increasing endogenous diacylglycerol by inhibit-
ing DAG kinase also failed to affect PKC in response to
TGF-h1. In general, diacylglycerol is produced as a rapid
response to receptor activation, but TGF-h1-dependent PKC
is a delayed response, implicating a regulatory cascade. Our
results indicate that no component of the cascade mediates
its effects via PLC or diacylglycerol, since DOG or the
DAG kinase inhibitor were present throughout the 12-h
incubation. This supports our previous observation showing
that the stimulatory effect of TGF-h1 on PKC activity does
not involve PLC, based on the inhibition of PLC activity
with the PI-PLC inhibitor U73122 [20]. It also rules out the
possibility of a role for diacylglycerol produced through a
PLD-dependent mechanism.
As noted previously for resting zone cells [22] and renal
tubular epithelial cells [74], G-proteins also mediate the
effects of TGF-h1 on PKC in growth zone chondrocytes,
since the general inhibitor GDPhS blocked PKC stimulation
in response to the growth factor. Both Gi and Gs appear to
be involved. TGF-h1 stimulation of PKC can be blocked by
pertussis toxin, which inhibits Gi, leading to an increase in
cAMP. In addition, TGF-h1 stimulation is blocked by
choleratoxin, indicating that Gs also plays a role. Choler-
atoxin activates the as subunit, so that cAMP is continu-
ously being produced [75]. This again implicates PKA in
the mechanism, but suggests that cAMP levels are important
variables in mediating the response to the growth factor.
Part of the effect of TGF-h1 on PKC in growth zone cells
is mediated by the PLA2 pathway. Arachidonic acid, the
product of PLA2 action, by itself increased PKC activity in
the cells, and at the highest concentration used, was additive
with TGF-h1. This differs from our previous observations
using resting zone cells, where activation of PLA2 inhibits
the stimulatory effect of TGF-h1 on PKC [29]. In addition,
exogenous arachidonic acid inhibits PKC activity in resting
zone cells [30], underscoring the role of cell maturation in
the mechanism.
Arachidonic acid is a known activator of PKC, acting in
part through direct nongenomic mechanisms [76,77]. It also
may increase PKC by activating gene expression via PPAR
receptors [78]. Arachidonic acid is also the substrate for
cyclooxygenase, resulting in prostaglandin production.
TGF-h1 stimulated PGE2 release into the conditioned media
at the same dose and time that elicited maximal increases in
PKC activity, suggesting that PGE2 might mediate the effect
of the growth factor on PKC. Exogenous PGE2 stimulated
PKC, as reported previously [47], but the increase was less
than that achieved by TGF-h1 alone. This suggests that
PGE2-dependent mechanisms may be involved, but are not
sufficient to elicit the complete PKC response. Our results
indicate that prostaglandins other than PGE2 play a role
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since the general cyclooxygenase inhibitor indomethacin
blocks the TGF-h1-dependent increase in PKC.
It is likely that the regulatory step is at PLA2 and
production of arachidonic acid. Previously, we have
reported that TGF-h1 decreases PLA2 in plasma membranes
and matrix vesicles in cultures treated for 24 h with the
growth factor [6]. It is clear from the present study, however,
that TGF-h1 increases PGE2 production. Since PGE2 is
derived from arachidonic acid, these results suggest that
TGF-h1 may cause an increase in PLA2 activity at an earlier
time point, resulting in a greater pool of arachidonic acid.
The increase in PGE2 levels is not due to an increased rate
of metabolism of arachidonic acid because only inhibition
of Cox-1, the constitutive form of cyclooxygenase, blocked
the TGF-h1-dependent effect. Inhibition of Cox-1 mim-
icked the effect of indomethacin, which inhibits both Cox-
1 and Cox-2. In contrast, inhibition of Cox-2 had no effect
on TGF-h1-dependent PKC.
Exogenous PGE2 has multiple effects on growth zone
cells, promoting differentiation and anabolic responses via
cAMP production and PKC activity [49]. Prostaglandins
exert their effects on cells via EP receptors, which are G-
protein-coupled, potentially accounting for the inhibition in
PKC activity when G-proteins are inhibited. Growth zone
chondrocytes express both EP1 and EP2, as well as a variant
of EP1, EP1v [51]. Previous studies showed that PGE2
directly increased PKC via EP1. However, EP1 signals
through PLCh [52], and the effect of TGF-h1 does not
involve PLC. PGE2 can also increase PKC indirectly
through EP2 receptor activation by signaling through cAMP
production and PKA [52], although this mechanism is not
used in control cultures of growth zone cells treated with
EP2 agonists [51]. This pathway may contribute to PKC
activation in response to TGF-h1, however, since inhibition
of PKA with H-8 caused a reduction in TGF-h1-induced
PKC activity. Moreover, H-8 reduced the TGF-h1-depend-
ent increases in [3H]thymidine incorporation and ALPase
activity.
In summary, the results of this study show that the effects
of TGF-h1 on growth zone chondrocytes are mediated by
the type II receptor involving at least three separate path-
ways: via PKC, PLA2/arachidonic acid/prostaglandin, and
PKA. Additionally, there is cross-talk between these path-
ways (see Fig. 7). In this schematic diagram, TGF-h1 binds
to its type II receptor, which binds to the type I receptor.
TGF-h1 type I receptor activates Smad proteins and also
activates a G-protein-dependent cascade, altering the activ-
ity of PLA2, which produces arachidonic acid. Depending
upon the time it is measured, PLA2 activity may either be
activated or inhibited, as indicated by the ‘‘F’’. Arachidonic
acid is metabolized by cyclooxygenase to prostaglandins,
which bind to EP1 and EP2 receptors on the growth zone
chondrocyte cell surface [51]. EP1 signaling stimulates PKC
activity, while EP2 signaling increases cAMP, which acti-
vates PKA. This suggests that TGF-h1 signals through PKC
and PKA to increase ALPase activity and to stimulate
Fig. 7. Mechanisms of TGF-h1 action in growth zone chondrocytes. Transforming growth factor-h1 (TGFh1); phospholipase A2 (PLA2); arachidonic acid
(AA); prostaglandin E2 (PGE2); alkaline phosphatase (ALPase); protein kinase A (PKA); protein kinase C (PKC); ‘‘’’= inhibition, ‘‘+’’=stimulation,
‘‘F’’= inhibition or stimulation, time-dependent. See last paragraph of Discussion for additional details.
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proliferation and through PKC to stimulate proteoglycan
production. Therefore, the regulation of the PKC pathway,
the PKA pathway and the PLA2/arachidonic acid/prosta-
glandin pathway by TGF-h1 is essential for its role in the
proliferation and differentiation of growth plate chondrocytes.
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